Axitinib in the treatment of renal cell carcinoma: patient selection and perspectives.

ABSTRACT:

Background

Axitinib is a next-generation, selective tyrosine kinase inhibitor targeting the vascular endothelial growth factor receptors. It is approved for the treatment of metastatic renal cell carcinoma (mRCC) based on a demonstrated progression-free survival advantage over sorafenib in the second-line treatment setting. However, given the variety of available targeted therapies for mRCC, appropriate patient selection for the available therapies remains a significant clinical challenge.

Purpose

This review summarizes the available evidence on the clinical, toxicity, and pharmacologic considerations for determining appropriate patient selection for axitinib therapy. In addition, it describes recent data on the use of predictive biomarkers to guide clinical management. This

SUBMITTER: Narayan V 

PROVIDER: S-EPMC4822864 | biostudies-literature | 2016

REPOSITORIES: biostudies-literature